A consistent production system in accordance with global quality standards, contract manufacturing of pharmaceutical raw materials with high quality, low cost, and short delivery times!
Our company utilizes unique chiral technologies such as enzyme methods, asymmetric synthesis, and optical resolution to undertake contract manufacturing not only of pharmaceutical active ingredients but also of raw materials for investigational drugs that our customers are developing. To provide high-quality pharmaceutical active ingredients at low cost and with stable supply, we invest in total manufacturing technologies, including the design and engineering of production facilities, for the construction of each plant. Additionally, our integrated production system in a multipurpose factory not only realizes the streamlining and efficiency of processes but also flexibly accommodates production "from tons to grams," meaning we can handle everything from large-volume batch production to small-batch production of various products. We have established a flexible production system, and our diverse production facilities that can cater to a wide range of scales have received positive feedback from many customers. *For more details, please download the PDF or feel free to contact us.
Inquire About This Product
basic information
【Manufacturing Factory/Equipment】 ■Integrated production system utilizing comprehensive manufacturing technology ■Achieving both high efficiency and environmental conservation *For more details, please download the PDF or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please download the PDF or feel free to contact us.
catalog(1)
Download All CatalogsCompany information
Since our establishment in 1946, we have been providing high-quality pharmaceutical raw materials, intermediates, vitamins, and fine chemical products using our unique organic synthesis technology. Since 2007, we have become a subsidiary of Kyowa Hakko Bio Co., Ltd., which is part of the Kirin Group, and we have shifted our business focus from fine chemicals to pharmaceuticals, concentrating our efforts on the development and expansion of our business in the pharmaceutical-related fields.

